Genentech Removing Raptiva From U.S. Market
Announcement Follows Reports of Three Deaths Associated With Use of Psoriasis Drug
By News Staff
4/10/2009
Four other biologic agents have been approved for treatment of psoriasis:
- adalimumab, which is marketed as Humira;
- alefacept, which is marketed as Amevive;
- etanercept, which is marketed as Enbrel; and
- infliximab, which is marketed as Remicade.
The FDA announced last October that it was requiring Genentech to make labeling changes, including the addition of a boxed warning, to highlight the risks associated with use of efalizumab.
In February, the agency issued a public health advisory after three patients who used efalizumab died. The FDA said that there had been three confirmed reports and one possible case of progressive multifocal leukoencephalopathy, or PML, in adults using the drug since it was approved in 2003. All four patients, who ranged in age from 47 to 73 years, had been treated with efalizumab for more than three years; none of them had received other treatments that suppress the immune system while taking the drug.
Three of the patients -- two with confirmed PML and one with possible PML -- died.
In an April 8 news release announcing the withdrawal, the FDA said that efalizumab will not be available in the United States after June 8.
Genentech said it is phasing out the drug during the two-month window to give patients time to transition to another medication. Severe psoriasis can potentially worsen with abrupt discontinuation of efalizumab, according to the company.
The FDA said doctors should continue to monitor patients using the drug for neurologic symptoms that might represent PML, including unusual weakness, loss of coordination, changes in vision, difficulty speaking and personality changes.
Physicians and patients may report adverse events to the FDA's MedWatch program at (800) FDA-1088 or online. Doctors with questions about Raptiva may contact Genentech at (800) 821-8590.
Genentech estimates that about 2,000 patients in the United States currently are using efalizumab for chronic plaque psoriasis. The manufacturer said its U.S. sales of Raptiva in 2008 were about $108 million.
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Pregnant Women
FDA Revises Diabetes Drug Prescribing Information
H1N1 Vaccine Availability Increasing Slowly
ACIP Supports 'Permissive Use' of Gardasil in Males
CDC Survey Shows Overall Gains in Teens' Immunization Rates
FDA Approves Gardasil for Males, Bivalent HPV Vaccine for Girls, Women
New USP Standards for Heparin Decrease Unit Dose Potency
H1N1 Vaccine Deliveries Begin This Week
Clinical Trial of H1N1 in Kids, Teens Shows Mixed Results
Physicians Should Use Caution With Tamiflu Dosages
Prostate Cancer Awareness Campaigns Could Cause Confusion
Federal Health Officials Push H1N1 Vaccine for Adults, Health Workers
IOM: N95 Respirators Offer H1N1 Flu Defense for Health Personnel
CDC Updates Recommendations for Antiviral Use
CDC Updates Guidance on Ophthalmia Neonatorum Prophylaxis
New AHRQ Guides Outline Gestational Diabetes Treatment Options
Erythromycin Ophthalmic Ointment in Short Supply
CDC, FDA Study Reinforces Safety, Efficacy of Gardasil
New GSK Product Should Ease Hib Vaccine Shortage
H1N1 Vaccine Clinical Trials in Adults Free of Adverse Events
AAFP Launches Awareness Campaign for Pertussis Vaccination
H1N1 Vaccine Production Lagging Behind Expectations
FDA Issues Multiple Safety Alerts, Updates
ACIP Updates Poliovirus Vaccination Recommendations
Research Network Seeks Evidence to Support Collaborative Care
Vaccines & Immunizations Special Report
ACIP Issues Targeted Recommendations for H1N1 Vaccinations
CDC Pushes Seasonal Flu Shots for Kids Ages 6 Months to 18 Years
FDA Issues Health Advisory for Raptiva
Psoriasis Drug Associated With Three Deaths
(2/24/2009)
Additional Resource
National Psoriasis Foundation: Treating Psoriasis








